BLA 125377 · Bristol Myers Squibb
Yervoy
Ipilimumab · Injection · CTLA-4-directed Blocking Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Mar 25, 2011
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
880
90 Phase 3, 137 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Ipilimumab" as an intervention, any sponsor and status, largest first.
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02872116 · 2,031 participants · Start Oct 12, 2016 · Primary completion May 27, 2020
Drug: Nivolumab; Ipilimumab and 4 more · For: Gastric Cancer; Gastroesophageal Junction Cancer; Esophageal Adenocarcinoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 179 sites in all
- An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03068455 · 1,844 participants · Start Apr 11, 2017 · Primary completion Jun 12, 2020
Drug: nivolumab; ipilimumab · For: Melanoma
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 124 sites in all
- MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00094653 · 1,783 participants · Start Sep 2004 · Primary completion Aug 2009
Drug: MDX-010 (anti-CTLA4) monoclonal antibody; MDX-1379 (gp100) Melanoma Peptide Vaccine · For: Melanoma; Metastases
Sites: Tucson, Arizona; Duarte, California; Encinitas, California · 209 sites in all
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT01274338 · 1,673 participants · Start Jun 17, 2011 · Primary completion Feb 15, 2019
Drug: Ipilimumab; Recombinant Interferon Alfa-2b · For: Melanoma of Unknown Primary; Recurrent Melanoma; Stage IIIB Cutaneous Melanoma AJCC v7 and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 937 sites in all
- A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03138512 · 1,641 participants · Start Jul 7, 2017 · Primary completion Sep 28, 2023
Drug: nivolumab; ipilimumab and 2 more · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; Springdale, Arkansas; Los Angeles, California · 200 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Yervoy (Ipilimumab)
2024 spending
$12.1M
Beneficiaries
203
623 claims
Per beneficiary
$59,562
$851.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,843,491 |
| 2021 | $9,418,195 |
| 2022 | $13,426,361 |
| 2023 | $13,234,453 |
| 2024 | $12,091,036 |
Part B: Yervoy (Ipilimumab) · HCPCS J9228
2024 spending
$509M
Beneficiaries
8,483
23,654 claims
Per beneficiary
$59,960
2024 ASP limit $174.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $366,039,293 |
| 2021 | $408,091,303 |
| 2022 | $443,655,803 |
| 2023 | $459,107,360 |
| 2024 | $508,639,690 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank CU, Lucas MW, Scolyer RA, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, et al. · JAMA Oncol 2018 · Meta-Analysis, Systematic Review
- Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
André T, Elez E, Lenz HJ, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.